drugset / Trial / NCT02249663

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

NCT02249663

Phase 3 Unknown 1535 enrolled Teva Pharmaceuticals USA
RandomizedParallel-groupQuadruple-blind

Summary

To evaluate the therapeutic equivalence of a test formulation of Azelastine hydrochloride and Fluticasone propionate Nasal Spray to the reference listed drug, Dymista™ Nasal Spray in the relief of the signs and symptoms of Seasonal Allergic Rhinitis.

Timeline

Start
2014-08
Primary completion
2015-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelastine Small molecule 137 ug Other
Subject Fluticasone propionate Other / unclassified 50 ug Other